Skip to main navigation Skip to search Skip to main content

Regulation of the NRG1/ErbB4 Pathway in the Intrinsic Cardiac Nervous System Is a Potential Treatment for Atrial Fibrillation

  • Xiaoya Zhou
  • , Zhuo Wang
  • , Bing Huang
  • , Shenxu Yuan
  • , Xia Sheng
  • , Lilei Yu
  • , Guannan Meng
  • , Yuhong Wang
  • , Sunny S. Po*
  • , Hong Jiang*
  • *Corresponding author for this work
  • Zhejiang Univ
  • Univ Oklahoma

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

["Background: The NRG1/ErbB4 signaling mechanism has been widely studied in the central nervous system for many years. However, the role of this pathway in modulating the intrinsic cardiac nervous system is largely unknown.","Objective: The present study investigated whether the NRG1/ErbB4 signaling system affects the activity of major atrial ganglionated plexi (GP) in a paroxysmal atrial fibrillation (AF) model by 6-h rapid atrial pacing (RAP).","Methods: Twenty-four dogs were randomly divided into (1) a control group (saline microinjections into GP), (2) RAP group (saline microinjections into GP plus 6 h-RAP), (3) NRG1 group (microinjections of neuregulin-1 into GP plus 6 h-RAP) and (4) NRG1 C ERA group (microinjections of neuregulin-1 and ErbB4 receptor antagonist-ERA into GP plus 6 h-RAP). The effective refractory period (ERP), window of vulnerability (WOV), anterior right GP (ARGP) function and neural activity were measured. ARGP tissues were excised for histological study and western blotting.","Results: When compared to the control group, 6 h-RAP produced a significant (1) decrease in ERP, an increase in 6 WOV, (2) an increase in ARGP neural activity and neural function, and (3) an increase in c-fos and nerve growth factor protein expression in the ARGP. However, microinjection of NRG1 into the ARGP prior to RAP prevented ERP shortening and AGRP activity enhancement and inhibited the expression of c-Fos and NGF proteins. Furthermore, these changes were significantly attenuated by pretreatment with an ErbB4 receptor antagonist.","Conclusion: The NRG1/ErbB4 signaling pathway may exist in the GP, and activation of this pathway suppressed RAP-induced GP activation, atrial electrical remodeling and AF."]
Original languageEnglish
Article number1082
Number of pages9
JournalFRONTIERS IN PHYSIOLOGY
Volume9
DOIs
StatePublished - 21 Aug 2018

Funding

This work was supported by the National Key R&D Program of China [2017YFC1307800], the National Natural Science Foundation of China [81470597, 81530011, 81570463, 81600395, and 81700444], the Natural Science Foundation of Hubei Province [2016CFA065, 2016CFA048, and 2016CFB621], the Health Department Foundation of Zhejiang Province [2012RCB024], the Foundation of Health and Family Planning Commission of Hubei Province [WJ2017C0005], and the Fundamental Research Funds for the Central Universities (Grant Number 2042018kf0102).

Keywords

  • neuregulin-1
  • ErbB4
  • atrial fibrillation
  • autonomic nervous system
  • ganglionated plexi

Indexed by

  • SCIE
  • Scopus

Fingerprint

Dive into the research topics of 'Regulation of the NRG1/ErbB4 Pathway in the Intrinsic Cardiac Nervous System Is a Potential Treatment for Atrial Fibrillation'. Together they form a unique fingerprint.

Cite this